Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Calcium-binding protein 2 (CaBP2) is a member of the EF-hand calcium-binding protein family that regulates neuronal calcium signaling, especially in the auditory system[1][2][3]. It is structurally related to calmodulin but exhibits more brain- and retina-enriched expression patterns. CaBP2 is highly expressed in inner hair cells of the cochlea, where it helps to sustain synaptic transmission crucial for sound encoding by attenuating voltage- and calcium-dependent inactivation of L-type calcium channels, particularly CaV1.3[2][3]. Loss-of-function mutations in CABP2 cause autosomal recessive nonsyndromic hearing loss (DFNB93), but it is not currently a therapeutic drug target[3].
Not therapeutically targeted; endogenous mechanism is inhibition of calcium channel inactivation, supporting sustained calcium influx and synaptic transmission[2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Calcium-binding protein 2 (CaBP2).